Dyne Therapeutics Ownership | Who Owns Dyne Therapeutics?

Dyne Therapeutics Ownership Summary

Dyne Therapeutics is owned by 116.14% institutional investors, 0.25% insiders. T. rowe price investment management is the largest institutional shareholder, holding 18.73% of DYN shares. T. Rowe Price US Small-Cap Core Equity is the top mutual fund, with 4.24% of its assets in Dyne Therapeutics shares.

DYN Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Dyne Therapeutics	116.14%	0.25%	-16.39%
Sector	Healthcare Stocks	245.07%	12.10%	-157.17%
Industry	Biotech Stocks	380.48%	11.73%	-292.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
T. rowe price investment management	30.91M	18.73%	$686.56M
Janus henderson group	13.65M	10.63%	$247.43M
Blackrock	7.39M	9.11%	$260.69M
Vanguard group	11.22M	7.91%	$219.38M
Blackrock funding, inc. /de	12.40M	7.52%	$275.50M
Fmr	11.21M	6.79%	$248.91M
State street	7.46M	4.52%	$165.65M
Orbis allan gray	7.01M	4.25%	$155.62M
Atlas venture life science advisors	6.80M	4.12%	$151.03M
Vanguard capital management	6.31M	3.82%	$140.17M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Mpm asset management	682.38K	19.40%	$8.63M
Atlas venture life science advisors	6.80M	17.14%	$151.03M
Fcpm iii services b.v.	3.85M	11.39%	$85.47M
University of wisconsin foundation	313.56K	5.51%	$6.96M
Palo alto investors lp	1.65M	5.06%	$36.59M
Saturn v capital management	1.06M	3.37%	$23.49M
Vivo capital	1.56M	3.16%	$34.59M
Bioimpact capital	1.92M	2.60%	$42.69M
Tcg crossover management	4.62M	2.46%	$102.50M
Logos global management lp	2.55M	2.44%	$56.64M

Top Buyers

Holder	Shares	% Assets	Change
Fmr	11.21M	0.01%	2.30M
Blackrock	7.39M	0.01%	2.00M
Paradigm biocapital advisors lp	1.90M	0.68%	1.90M
Price t rowe associates inc /md/	3.94M	0.01%	1.61M
Vanguard group	11.22M	0.00%	1.46M

Top Sellers

Holder	Shares	% Assets	Change
Ra capital management	-	-	-9.71M
Holocene advisors, lp	-	-	-2.35M
Atlas venture life science advisors	6.80M	17.14%	-2.33M
Perceptive advisors	2.69M	0.90%	-1.98M
Jefferies financial group	-	-	-1.80M

New Positions

Holder	Shares	% Assets	Change	Value
Paradigm biocapital advisors lp	1.90M	0.68%	1.90M	$24.02M
Sixth street partners management company	1.20M	0.00%	1.20M	$26.70M
Novo	960.39K	1.24%	960.39K	$21.33M
Granahan investment management	338.56K	0.27%	338.56K	$7.52M
Alyeska investment group	245.28K	0.01%	245.28K	$5.45M

Sold Out

Holder	Change
Dunhill financial	-1.00
Nelson, van denburg & campbell wealth management group	-9.00
Creative financial designs inc /adv	-10.00
J.safra asset management	-11.00
Twin peaks wealth advisors	-14.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2026	253	7.20%	191,678,138	2.03%	116	0.90%	140	-2.78%	74	21.31%
Mar 31, 2026	229	-4.58%	186,215,369	4.65%	144	0.92%	139	-9.74%	60	7.14%
Dec 31, 2025	48	-77.78%	17,667,612	-88.66%	12	0.07%	33	-77.40%	8	-80.49%
Sep 30, 2025	56	-72.00%	16,926,024	-86.84%	14	0.12%	39	-66.95%	9	-82.69%
Jun 30, 2025	198	-5.71%	128,546,973	5.45%	112	0.92%	116	-10.08%	52	15.56%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
T. Rowe Price US Small-Cap Core Equity	7.00M	4.24%	-7.60K
T. Rowe Price Small-Cap Stock	7.41M	3.97%	29.67K
Vanguard MStar Total Stk Mkt Idx Invest	5.26M	2.82%	-7.69K
Vanguard Total Stock Mkt Idx Inv	4.47M	2.71%	-242.06K
T. Rowe Price Small-Cap Value	4.61M	2.47%	-42.29K
Vanguard Morn Total Stk Mkt Idx Investor	4.47M	2.40%	-242.06K
State Street® SPDR® S&P® Biotech ETF	4.46M	2.39%	50.19K
Vanguard US Total Market Shares ETF	2.65M	2.35%	2.40K
T. Rowe Price Instl Small-Cap Stock	4.04M	2.17%	25.68K
iShares Russell 2000 ETF	4.03M	2.16%	34.46K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Sep 08, 2026	Friedl-Naderer Johanna	Chief Commercial Officer	Sell	$3.49K
Sep 04, 2026	Friedl-Naderer Johanna	Chief Commercial Officer	Sell	$21.91K
Sep 08, 2026	Kerr Douglas	Chief Medical Officer	Sell	$24.36K
Sep 04, 2026	Kerr Douglas	Chief Medical Officer	Sell	$91.19K
Sep 08, 2026	Cox John	CEO & President	Sell	$106.82K

Insider Transactions Trends

Date	Buy	Sell
2026 Q3	-	27
2026 Q2	4	84
2026 Q1	3	8
2025 Q4	-	3
2025 Q3	1	5

DYN Ownership FAQ

Who Owns Dyne Therapeutics?

Dyne Therapeutics shareholders are primarily institutional investors at 116.14%, followed by 0.25% insiders and -16.39% retail investors. The average institutional ownership in Dyne Therapeutics's industry, Biotech Stocks , is 380.48%, which Dyne Therapeutics falls below.

Who owns the most shares of Dyne Therapeutics?

Dyne Therapeutics’s largest shareholders are T. rowe price investment management (30.91M shares, 18.73%), Janus henderson group (13.65M shares, 10.63%), and Blackrock (7.39M shares, 9.11%). Together, they hold 38.47% of Dyne Therapeutics’s total shares outstanding.

Does Blackrock own Dyne Therapeutics?

Yes, BlackRock owns 9.11% of Dyne Therapeutics, totaling 7.39M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 260.69M$. In the last quarter, BlackRock increased its holdings by 2M shares, a 37.05% change.

Who is Dyne Therapeutics’s biggest shareholder by percentage of total assets invested?

Mpm asset management is Dyne Therapeutics’s biggest shareholder by percentage of total assets invested, with 19.40% of its assets in 682.38K Dyne Therapeutics shares, valued at 8.63M$.

Who is the top mutual fund holder of Dyne Therapeutics shares?

T. Rowe Price US Small-Cap Core Equity is the top mutual fund holder of Dyne Therapeutics shares, with 4.24% of its total shares outstanding invested in 7M Dyne Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools